# US 2023/0265118 A1 · Salt of curcumin monoglucuronide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265118 A1
- Document ID: US20230265118A1
- Status: Published application
- Kind: A1
- Application number: 18/004,023
- Filed: 2021-07-02
- Published: 2023-08-24
- Earliest claimed: 2020-07-02
- Assignees: Therabiopharma Inc.
- Applicants: Therabiopharma Inc.
- Inventors: Atsushi IMAIZUMI; Hitomi UMETA; Yasumichi FUKUDA
- Web page: https://patentgrep.com/patent/US20230265118A1

## CPC

- C07H 15/207: Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/06: Free radical scavengers or antioxidants
- C07H 15/203: Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a derivative of curcumin monoglucuronide excellent in solubility and chemical stability, which can be provided as pharmaceuticals, and a method for producing the same. A salt of curcumin monoglucuronide represented by Chemical Formula 1, wherein M represents a pharmaceutically acceptable cation, a hydrate thereof, or a solvate thereof.

## Claims

### Claim at position 1

1: A salt of curcumin monoglucuronide represented by Chemical Formula 1 below,
wherein M represents a pharmaceutically acceptable cation,
a hydrate thereof, or a solvate thereof.

### Claim at position 2 (depends on 1)

2: A compound according to claim 1, M being a sodium ion, a potassium ion, or an ammonium ion.

### Claim at position 3 (depends on 1)

3: A method of preparing the compound according to claim 1, wherein a curcumin monoglucuronide is reacted with a base represented by Chemical Formula (II) below,
Mm-Y (II)
wherein M represents a pharmaceutically acceptable cation, Y represents an anion, and in represents an integer from 1 to 3.

### Claim at position 4 (depends on 3)

4: The method according to claim 3, wherein M is a sodium ion, a potassium ion or an ammonium ion, Y is a hydroxide ion, and m is 1.

### Claim at position 5 (depends on 1)

5: A pharmaceutical composition comprising the compound according to claim 1.

### Claim at position 6 (depends on 5)

6: The pharmaceutical composition comprising a solution of the compound according to claim 5, for parenteral administration.

### Claim at position 7

7-9. (canceled)

### Claim at position 8 (depends on 5)

10: A method of treating or preventing a disease with curcumin comprising administering the composition of claim 5

### Claim at position 9 (depends on 10)

11: The method of claim 10 wherein the pharmaceutical composition comprises an aqueous solution.

### Claim at position 10 (depends on 11)

12: The method of claim 11 wherein the composition is administered intravenously.
